Compare Global X Autonomous & Electric Vehicles (DRIV) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Tango Therapeutics Inc. — how do they compare? Global X Autonomous & Electric Vehicles trades at $30.99 (market cap $357.19M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 10.5× Global X Autonomous & Electric Vehicles's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Global X Autonomous & Electric Vehicles nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 41 Days and Tango Therapeutics Inc. for 0 Days on average.
| DRIV | TNGX | |
|---|---|---|
Market Cap | $357.19M | $3.75B |
Volume | 24,175 | 9,619,106 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $32.90 |
52-Week Low | $27.60 | $7.50 |
Typical Hold Time | 41 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.06, down slightly by 0.06% today. Technical indicators show mixed signals with a bullish overall signal but bearish moving averages. The stock faces resistance at $34 with support at $33. Recent news highlights automotive sector dynamics including hybrid vehicle growth and China's EV ambitions, which could impact DRIV's market positioning.
The outlook for DRIV is cautiously optimistic given sector tailwinds from hybrid and EV adoption, though key financial ratios remain unavailable for fundamental assessment. Risks include oil price volatility and competitive pressures. Analyst sentiment appears balanced with equal buy/sell technical signals, suggesting investors should monitor upcoming earnings for clearer direction.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
